NYMX
NASDAQ : NYMX

NYMX

September 08, 2005 12:43 ET

Nymox Signs Marketing Agreement With Brainpharma S. L. For AlzheimAlert™ Kit to Be Sold in Spain

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 8, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has entered into an agreement with Brainpharma S.L. for the marketing and sale of Nymox's AlzheimAlert™ product in Spain. AlzheimAlert™ provides physicians with a valuable tool for the diagnosis of Alzheimer's disease by measuring levels of a biomarker for Alzheimer's disease in patient urine samples. Brainpharma is an international pharmaceutical company headquartered in Spain formed by Grupo Ferrer Internacional S.A. and Farmalider S.A. to develop and commercialize health care products in the domain of neuropsychiatry.

"We welcome the opportunity to bring the painless, accurate and cost-effective urine test AlzheimAlert™ to aid physicians in the diagnosis of Alzheimer's disease. and to take advantage of new improvements in drug treatment and care", Dr Ana Jimenez, Member of the Board of Brainpharma, commented. "Both companies are encouraged by the opportunities that Nymox technology presents for both the short and long term."

""We are pleased to be working with Brainpharma to make our AlzheimAlert™ kits available to physicians and laboratories in Spain", said Brian Doyle, Nymox's Senior Manager for Worldwide Sales and Marketing. "Its commitment to the development and commercialization of high quality, affordable and innovative drugs and diagnostic and therapeutic tests and tools for neurological and psychiatric disorders makes it the ideal partner for launching AlzheimAlert™ in Spain. With this agreement, Spain joins Greece, Italy and the Czech Republic as EU countries in which we have major distribution agreements for our AlzheimAlert™ product."

The AlzheimAlert™ test uses state-of-the-art technology to measure the level of a brain protein called neural thread protein (NTP) found in higher amounts in the urine of patients suffering from Alzheimer's disease. The test provides valuable information for physicians in the often difficult task of Alzheimer's disease diagnosis and is the only test of its kind.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com